Every 10-Q that Tyra Biosciences, Inc. (TYRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.
Tyra Biosciences, Inc., a clinical-stage FGFR-focused biotech, reports continued operating losses as it advances its pipeline. For the three months ended June 30, 2026, net loss was $45.6 million on operating expenses of $49.0 million, including research and development expense of $39.2 million and general and administrative expense of $9.8 million. For the first half of 2026, net loss was $84.9 million on research and development expense of $72.7 million and general and administrative expense of $18.3 million, with no product revenue.
The company highlights progress across oral dabogratinib Phase 2 trials in LG-UTUC (SURF303), IR NMIBC (SURF302) and achondroplasia (BEACH301), plus TYRA-430 in FGF19+ HCC and TYRA-200 in FGFR2-driven ICC. Initial SURF302 results are expected in September 2026, with first BEACH301 and SURF303 readouts anticipated in 2027.
Liquidity remains a key focus: as of June 30, 2026, Tyra held $353.9 million in cash, cash equivalents and marketable securities. It raised $147.9 million in Q1 2026 via an at-the-market offering and subsequently amended that program to permit additional sales of up to $250.0 million, and management believes existing resources will fund operations into the second half of 2028.
Tyra Biosciences reported a larger net loss for the quarter ended March 31, 2026 as it increased investment in its pipeline. Net loss was $39.3 million, compared with $28.1 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $33.5 million, while general and administrative costs were $8.5 million. The company strengthened its balance sheet by raising $147.9 million via an at-the-market stock program, ending the quarter with $383.5 million in cash, cash equivalents and marketable securities and stating this should fund operations into the second half of 2028.
Tyra Biosciences (TYRA) reported a wider quarterly net loss as it advanced multiple clinical programs. For the three months ended September 30, 2025, the company posted a net loss of $29.9 million versus $24.0 million a year ago. Operating expenses rose to $32.9 million, driven by R&D of $25.5 million and G&A of $7.5 million, while interest and other income contributed $3.1 million.
Liquidity remains strong with cash, cash equivalents and marketable securities of $274.9 million as of September 30, 2025. Net cash used in operations was $71.5 million for the first nine months of 2025. Management states this cash position is expected to fund operations through at least 2027.
Development highlights include progress across FGFR programs: dabogratinib Phase 2 studies in pediatric achondroplasia (BEACH301) and NMIBC (SURF302) are underway, UTUC (SURF303) received FDA clearance to initiate Phase 2, and TYRA-430 began dosing in a global Phase 1. Shares outstanding were 53,318,198 as of September 30, 2025; 53,372,098 were outstanding as of October 31, 2025.
Tyra Biosciences (TYRA) reported items from its Quarterly Report that describe capital structure, recent equity transactions, stock plan availability, cost drivers and development risks. The company had 53,233,494 shares issued and outstanding at June 30, 2025, compared with 50,754,262 issued and 50,749,945 outstanding at December 31, 2024. A 2022 Sales Agreement was terminated in May 2025 and no shares were sold under it; no shares had been sold under a 2025 Sales Agreement as of June 30, 2025. RA Capital exchanged 1,000,000 shares for pre-funded warrants exercisable at $0.001 per share; the Exchange closed October 22, 2024, and the warrants are classified in stockholders' equity. As of June 30, 2025, 5,189,786 shares were available for future grant under the 2021 Plan and 1,972,762 shares remained available for purchase under the ESPP, which offers a purchase price at 85% of the lower of two dates. The company disclosed increases in costs: $4.1 million and $9.6 million driven by clinical start-up and CMC activities, and increases of $2.4 million and $4.5 million in compensation and personnel expenses (including $1.0 million and $2.2 million higher stock-based compensation), partially offset by $0.2 million lower facilities costs. The filing lists numerous development, regulatory, operational and geopolitical risks that could affect timelines, costs and commercialization prospects.